With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Athletics New Zealand is delighted to announce the addition of the short track championships, set to debut at the Mitre 10 ...

Debt-to-equity ratios vary by company and industry, but in general, a ratio of 1.0 or less is considered rather safe. One of ...

The Department of Internal Affairs, Te Tari Taiwhenua, has released the most popular Māori baby names for 2024/2025. For the third consecutive year, Aroha/Te Aroha/Te-Aroha/TeAroha (173) topped the ...

Merck’s first quarter results drew a positive market reaction, reflecting operational resilience despite a 1.6% ...

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

Only a few days prior, Sanofi also stated that it would simplify its R&D structure, ... (Eliquis), Johnson & Johnson (Stelara), and Merck (Keytruda), among others.

The space environment is not kind to human bodies. The final frontier may therefore be the perfect place to study cancer — and someday even treat it.

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. | Merck & Co.’s Keytruda has ...

Keytruda generated sales of $7.21 billion in the first quarter of 2025, rising 6% year over year. Our model estimates for Keytruda suggest a CAGR of 5.4% over the next three years. MRK’s Price ...

While Merck faces the inevitable Keytruda patent cliff in 2028, the company is positioning itself for continued growth through strategic diversification and pipeline expansion. Earlier this month ...

Nonetheless, though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then. Merck is also working on different strategies to drive Keytruda's long-term ...